Hosted by Aditya Basu · 🇺🇸 US · EN · 17 episodes
Established thought leaders with verified media credentials.
NexTechie BioFlux: Tracking the Tech That Heals, Evolves, and Informs.Biotechnology and health innovation are transforming the way we live, heal, and understand the human body. NexTechie BioFlux – The Brief delivers clarity, speed, and authority in a rapid 3‑minute audio overview designed for professionals, innovators, and decision‑makers who need to stay ahead of the biotech frontier. Every episode distills the most important breakthroughs, platforms, and strategies into a concise briefing that respects your time while expanding your perspective.BioFlux is more than just a podcast—it’s a strategic lens into the biotech revolution. Our anchors spotlight the cutting‑edge developments shaping medicine, genetics, and health technology, from CRISPR gene editing and synthetic biology to AI‑powered diagnostics and wearable health platforms. Whether it’s the latest in personalized medicine, breakthroughs in regenerative therapies, or policy debates around bioethics and data privacy, BioFlux
Aditya Basu hosts EN | BioFlux - The Brief (English), a news show with 17 episodes published.
Welcome to BioFlux, your essential update on the innovations redefining global healthcare. This edition highlights a transformative period for the industry, marked by the dismantling of "undruggable" targets and a radica
Show notesNexTechie BioFlux analyzes a week of profound therapeutic shifts, including Regeneron’s Phase III immuno-oncology setback and AstraZeneca’s landmark FDA approval of Baxfendy for hypertension. Concurrently, Candel Therape
Show notesThe biotech industry is entering a transformative era, marked by three landmark developments. First, the FDA’s historic approval of Veppanu, the first-ever PROTAC therapy, validates protein degradation as a powerful new
Show notesIn this edition of BioFlux, we explore a transformative shift in genetic medicine. Eli Lilly’s $7 billion acquisition of Kelonia Therapeutics signals a future where in vivo T-cell reprogramming replaces complex external
Show notesWelcome to BioFlux, your deep dive into the breakthroughs transforming modern medicine. This edition highlights the landmark FDA approval of Eli Lilly’s Foundayo, the first daily oral treatment for obesity. This breakthr
Show notesThis issue of BioFlux explores the cutting edge of biotech, focusing on Google’s groundbreaking MedGemma 1.5 and TxGemma AI models. These advancements are set to redefine clinical reasoning and therapeutic R&D. Complemen
Show notesWelcome to BioFlux! This week, we explore a historic seven-day clinical super-cycle that is fundamentally reshaping modern medicine. We break down unprecedented Phase 3 successes from Vertex, Bristol Myers Squibb, and Xe
Show notesNexTechie BioFlux - The Brief: Major Strategic Acquisitions and Spin-offs Reshaping the Future of Healthcare Welcome to NexTechie BioFlux, your guide to breakthroughs in biotech and medtech. This edition highlights Gilea
Show notesWelcome to BioFlux, dissecting AI's pivotal moment in biotech, medtech, and health tech. Artificial intelligence is rapidly evolving from theoretical potential to a tangible, value-driving force, fundamentally reshaping
Show notesThis BioFlux edition explores critical shifts in health tech, biotech, and medtech. We analyze the impending "telehealth cliff" as Medicare's pandemic flexibilities expire, impacting U.S. patient access and provider oper
Show notesWelcome to BioFlux, exploring breakthroughs in biotech, medtech, and health tech. This edition focuses on Legend Biotech's CARVYKTI® CAR-T therapy, poised to revolutionize multiple myeloma treatment by moving to earlier
Show notesWelcome to BioFlux, your guide to biotech, medtech, and health tech breakthroughs. This edition dissects a surprising regulatory setback: Atara Biotherapeutics received a second FDA Complete Response Letter for tabelecle
Show notesWelcome to BioFlux, your source for biotech, medtech, and health tech insights. This edition navigates the complex landscape of advanced therapeutics. We address the critical partial clinical hold placed on Daiichi Sanky
Show notesNexTechie BioFlux delves into the dynamic future of Biotech, MedTech, and Health Tech. This edition showcases mRNA technology's revolutionary expansion into oncology, with personalized cancer vaccines demonstrating remar
Show notesThis edition of NexTechie BioFlux dives into the profound integration of AI across medical diagnostics. The central theme explores how artificial intelligence is transforming medical imaging and pathology from mere inter
Show notesWelcome to NexTechie BioFlux! This edition explores pivotal forces reshaping Biotech, MedTech, and Health Tech. We highlight India's groundbreaking indigenous Quantum Diamond Microscope, set to revolutionize cancer diagn
Show notes
In this edition, we dissect the explosive impact of Artificial Intelligence across the entire healthcare continuum. We begin with our central theme, exploring how AI is making a monumental diagnostic leap, evolving every
Show notesWelcome to NexTechie BioFlux - The Brief. Your smart dive into tech that heals, evolves, and informs. In this edition, we dissect Medicxi's landmark €500M fund and what its 'asset-centric' strategy means for the entire i
Show notesSponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
EN | BioFlux - The Brief (English) has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their news audience.
EN | BioFlux - The Brief (English) is hosted by Aditya Basu. The show is categorised under news and has published 17 episodes.
EN | BioFlux - The Brief (English) has published 17 episodes.
EN | BioFlux - The Brief (English) regularly covers news. It sits in the news category.
EN | BioFlux - The Brief (English) is accessible for guests with genuine news expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
EN | BioFlux - The Brief (English) hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of EN | BioFlux - The Brief (English) average 3 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates EN | BioFlux - The Brief (English)'s guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 12 days ago.
